SOUTH EASTON, Mass., March 1, 2016 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced it has closed the first tranche of the over-subscription amount of its $5 million Private Placement (the "Offering") following the receipt of $550,000 in gross proceeds from the sixth overall closing of the Offering.  This closing increased the total amount raised in the Offering to $5,560,000.

The initial terms of the Offering limited the amount that could be raised in the Offering to $6.25 million ($5 million plus a $1.25 million over-subscription amount).  The Company recently approved an increase in the over-subscription amount to $2.5 million, which increased the capacity of the Offering to a maximum of $7.5 million.  Following the sixth closing, $1,940,000 remains available in the Offering.

Pursuant to the terms of the Offering, the Company will issue to the investors, senior secured convertible debentures with a fixed conversion price of $0.28 per restricted common share, and common stock purchase warrants exercisable into shares of restricted common stock at an exercise price of $0.40 per share. The Company is under no obligation to file a registration statement to register the shares underlying the Debentures and Warrants.

Mr. Richard T. Schumacher, President and CEO of PBI, commented: "In mid-January 2016, SCIEX, a global leader in life science analytical technologies and a wholly-owned subsidiary of the Danaher Corporation, announced an exclusive co-marketing agreement with PBI.  Under the agreement, the companies will jointly promote PBI's PCT-based sample preparation systems and SCIEX's mass spectrometry equipment, with a focus on improved sample preparation, a crucial step performed by tens of thousands of research scientists worldwide."

Mr. Schumacher continued: "We believe the combination of PBI and SCIEX technologies could result in superior biological insights and discoveries in the life sciences industry, and in rapid and sustainable revenue growth for PBI.  It is therefore important to do everything possible to strongly support the PBI-SCIEX co-marketing agreement.  Consequently, we decided to increase the over-subscription amount to help ensure that we fulfill our obligations under the co-marketing agreement, and to enable us to take full advantage of the opportunities that the co-marketing agreement and new working relationship with SCIEX will most certainly offer."

This press release is not an offer to sell or a solicitation of offers to participate in the Offering. The units, including the shares underlying the Debentures and Warrants, have not been registered under the Securities Act and may not be sold in the United States absent registration under the Securities Act or an applicable exemption from registration.

For more information on the Offering, please see the Form 8-K filed by the Company on July 28, 2015.

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.      

Forward Looking Statements
Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2014, in the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2015, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:  
http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter

Investor Contacts:                                         
Richard T. Schumacher, President & CEO, PBI                       
(508) 230-1828 (T)  

Jeffrey N. Peterson, Chairman, PBI                                                     
(650) 812-8121 (T)

Redwood Investment Group             
(714) 978-4425 (T)

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pressure-biosciences-closes-550000-first-tranche-of-5-million-pipe-over-subscription-amount-300228652.html

SOURCE Pressure BioSciences, Inc.